Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Hyperuricemia is linked to increased cardiovascular disease (CVD) risk, including coronary artery disease and hypertension.
• Elevated uric acid levels contribute to adverse cardiovascular outcomes.

Purpose of the Study:

• To evaluate the impact of urate-lowering therapy on blood pressure and cardiovascular events in patients with hyperuricemia.
• To assess the cardiovascular safety of xanthine oxidase inhibitors.

Main Methods:

• Analysis of clinical trials and studies investigating urate-lowering treatments, specifically xanthine oxidase inhibitors like allopurinol and febuxostat.
• Review of data on blood pressure reduction and major adverse cardiovascular events (MACE).

Main Results:

• Urate-lowering therapy significantly reduces both systolic and diastolic blood pressure in individuals with hyperuricemia and hypertension.
• Treatment demonstrates a favorable effect on reducing systolic blood pressure and MACE in patients with prior CVD.
• Xanthine oxidase inhibitors (e.g., febuxostat) are non-inferior to allopurinol regarding cardiovascular safety, with no increased risk of mortality or serious adverse events.

Conclusions:

• Managing hyperuricemia through urate-lowering therapy is crucial for mitigating cardiovascular risks.
• Xanthine oxidase inhibitors are a safe and effective treatment option for reducing blood pressure and preventing cardiovascular events in at-risk populations.